

Association of Plasma Eicosanoid Levels With Immune, Viral, and Cognitive Outcomes in People With HIV

Pragney Deme, PhD,* Mohammed Moniruzzaman, PhD,* David Moore, PhD, Robert Heaton, PhD, Ronald Ellis, MD, PhD, Scott Letendre, MD, and Norman Haughey, PhD

Neurology® 2022;99:e1251-e1264. doi:10.1212/WNL.0000000000200945

Correspondence

Dr. Haughey
nhaughe1@jhmi.edu

Abstract

Background and Objectives

To determine whether plasma eicosanoid levels are associated with immune, viral, and cognitive outcomes in people with HIV (PWH).

Methods

We measured 42 eicosanoids in a longitudinal study of 95 PWH and 25 demographically comparable uninfected participants. Routine clinical chemistry, virologic, immune markers, and a neuropsychological test battery assessing 7 cognitive domains were administered to all participants at 2 study visits over an average of 6.5 months.

Results

Plasma eicosanoid concentrations were elevated in PWH ($n = 95$) compared with seronegative controls ($n = 25$) (100% prediction power at 5% false discovery rate [FDR], $\alpha = 0.0531$) and were negatively associated with lower current and nadir CD4 lymphocyte counts. Higher levels of eicosanoids were associated with impairments in working memory, verbal fluency, and executive function. Higher plasma viral load was associated with elevated proinflammatory eicosanoids (24% prediction power at 5% FDR and 42.4% prediction power at 10% FDR, $\alpha = 0.10$). Longitudinal analyses showed that eicosanoid levels were correlated with viral load and with plasma creatinine. Despite associations of eicosanoids with viral loads, elevated plasma eicosanoids were similar in virally suppressed and not fully suppressed PWH.

Discussion

These data show that HIV infection is associated with a robust production of eicosanoids that are not substantially reduced by antiretroviral therapy (ART). The sustained elevation of these oxylipins in PWH despite ART may contribute to an accelerated aging phenotype that includes earlier than expected brain and peripheral organ damage.

RELATED ARTICLE

Editorial

Neuroinflammation and HIV-Associated Cognitive Impairment: Can They Be Eradicated?

Page 499

*These authors contributed equally to this work.

From the Department of Neurology (P.D., M.M., N.H.), Johns Hopkins University School of Medicine, Baltimore, MD; HIV Neurobehavioral Research Program and Departments of Neurosciences and Psychiatry (D.M., R.H., R.E., S.L.), School of Medicine, University of California, San Diego, La Jolla; and the Department of Psychiatry (N.H.), Johns Hopkins University School of Medicine, Baltimore, MD.

Go to [Neurology.org/N](https://www.neurology.org/N) for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.

The Article Processing Charge was funded by the NIH.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Glossary

AA = arachidonic acid; ART = antiretroviral therapy; CI = cognitive impairment; DHA = docosahexaenoic acid; EPA = eicosapentaenoic acid; GDS = Global Deficit Score; HIV_{CI} = HIV cognitively impaired; HIV_{CN} = HIV cognitively normal; HIV_{SN} = HIV seronegative; iNOS = inducible nitric oxide synthase; LA = linoleic acid; NO = nitric oxide; PWH = people with HIV; SIP = speed of information processing; SPE = solid-phase extraction; TLR = toll-like receptor.

Antiretroviral therapy (ART) has proven to be effective in controlling replication of the human immunodeficiency virus (HIV).¹ Despite the efficacy of ART to suppress viral replication, immune dysfunction, chronic inflammation, organ damage, and cognitive impairment (CI) are still apparent in many people with HIV (PWH).² Although the precise mechanisms for these residual pathologies have been elusive, considerable clinical and experimental evidence has associated chronic inflammation with immune dysfunction and damage to multiple organ systems including brain.³

It is well known that the inflammatory cytokines elevated in PWH are largely, but not completely, reduced with suppressive ART.⁴ However, very little is known about the impact of ART on eicosanoid metabolism. Eicosanoids are bioactive lipids derived from the metabolism of polyunsaturated fatty acids (PUFAs) that are processed in 1 of 3 major pathways: cyclooxygenase, lipoxygenase, or cytochrome p450 epoxide pathways that each produce multiple biologically active metabolites. Eicosanoids play important roles in the regulation of numerous physiologic responses including those associated with vascular function, inflammation, and immune modulation⁵ (among others). Two papers in the early 1990s reported elevated CSF levels of the eicosanoids PGE₂, PGF₂ α , PGD₂, LTB₄, and TXB₂ in ART-naive PWH compared with HIV-negative control participants.^{6,7} Since that time, a number of studies have identified elevated levels of COX-1 and COX-2 metabolic products including prostaglandins, prostacyclins, and thromboxanes in HIV model systems and in human samples from PWH,^{8,9} but no studies to date have addressed the potential dysregulation of lipoxygenase and cytochrome p50 epoxide metabolic pathways in HIV. Similarly, the effects of ART on eicosanoid metabolism in PWH are unknown, as are the associations of eicosanoids with cognition in PWH. Here, we performed an extensive analysis of plasma eicosanoids with a focus on lipoxins and epoxides in ART-naive PWH, ART suppressed PWH, and uninfected healthy controls and report associations with clinical chemistry and cognitive functions.

Methods

Human Plasma Sample Collection

Plasma samples from PWH were obtained from the CNS HIV Antiretroviral Therapy Effects Research (CHARTER) study. Participant selection was based on a case review of ~3,500 clinical visits from 430 study participants as previously described.^{10,11} In brief, neurocognitive change was defined

using a multivariable change score approach. A Z-score was generated for each of 15 neuropsychological variables that reflect how well or poorly the participant performed at follow-up, relative to the expectation for someone with the same baseline neuropsychological and other relevant characteristics. Z-scores were summed to provide a summary regression change score. The central 80% of the summary regression change score distribution was defined as cognitively “stable.” The top 10% were defined as cognitively “improved,” and the bottom 10% defined as cognitively “declined.”¹⁰ All participants were carefully assessed for neuromedical and neuropsychiatric comorbidities and excluded if confounds not related to HIV were likely to be primary contributors to cognitive impairment as previously described.¹²

Standard Protocol Approvals, Registrations, and Patient Consents

The collection of human plasma samples was approved by the Institutional Review Board at each performance site. All participants provided informed consent for all study procedures, including future use of their stored specimens and data for research.

Neuropsychological Testing

Neuropsychological testing was conducted by trained neuropsychometricians and consisted of tests covering 7 cognitive domains: executive function, learning and delayed recall, working memory, verbal fluency, speed of information processing, and motor skills. The best available normative standards were used to convert the scores to demographically corrected standard scores (T-scores), which correct for effects of age, education, sex, and ethnicity.¹³ The presence and severity of CI were determined using the Global Deficit Score (GDS) approach, where a GDS \geq 0.5 was impaired.¹⁴ All follow-up visits were corrected for practice effects.¹⁵

Sample Preparation

Each plasma sample (200 μ L) was spiked with deuterium labeled internal standards representing several major classes of eicosanoids: AA-d₈, 13-HODE-d₄, 15(S) HETE-d₈, LXA₄-d₅, PGB₂-d₄, and LTC₄-d₅ (1 μ g/mL each). Solid-phase extraction (SPE) of eicosanoids was performed using Trace N, 15 mg, 10 μ m columns (SPEware Corporation) connected to a positive pressure SPE CEREX SYSTEM 48 processor (SPEware Corporation). Columns were preconditioned using 2 mL of methanol followed by 2 mL of water. Samples were loaded onto columns, washed with 2 mL of water and methanol mixture (95:5, vol/vol), and then eluted with 1 mL of pure methanol. Methanol eluent was dried under a stream of nitrogen using a

Multivap nitrogen evaporator (Model 118, Organomation Associates Inc) and stored at -80°C . Dried extracts were resuspended in pure methanol just before analysis.

Eicosanoids Analysis by LC-MS/MS

Plasma eicosanoids levels were measured by using LC-ESI-MS/MS. Chromatographic separation was performed by reverse-phase liquid-chromatography using a Luna 3 μm C18 250 \times 2-mm column (Phenomenex), coupled to a Shimadzu liquid chromatography (LC) (Shimadzu Scientific Instruments, Inc). Eluted samples were introduced into a triple stage quadrupole linear ion trap (4000QTRAP) mass spectrometer (Applied Biosystems) using multiple reaction monitoring in negative electrospray ionization mode (ESI). Instrument control and data acquisition were performed using Analyst 1.5.1 software. Data processing was performed using MultiQuant 1.2 software (Applied Biosystems).

Statistical Analyses

Because imputation of values below the limit of detection with a constant value can adversely affect statistical analyses by increasing the likelihood of biased parameter estimations that distort sample distribution and impair statistical power, in this study, undetectable values for each eicosanoid were replaced with a left-censored stochastic minimal value approach which imputes data by random draws from a Gaussian distribution centered in the minimal value which was estimated as being the q th quantile of the observed values (imputeLCMD package in R). Two-group comparisons were performed using the Wilcoxon test, and multiple group comparisons were accomplished using the Kruskal-Wallis test with the Dunn test for post hoc comparisons. Correlation analyses were performed using the Spearman rank correlation method, and the p values were corrected using the Benjamin-Hochberg (B-H) method for multiple comparison tests. The value of the effect size is considered low if the value of Spearman r correlation value was around 0.1, medium if around 0.3, and large if it is greater than 0.5. p values less than 0.05 were considered statistically significant. The power analysis was performed using MetaboAnalyst 5.0 to estimate sample size and the effect size of this study data to achieve prediction power greater than 80% at 5% false discovery rate false discovery rate [FDR].

Results

Participant Characteristics

This study included 120 participants grouped from baseline cognitive function as (i) HIV seronegative ($n = 25$), (ii) HIV cognitively normal ($n = 41$), and (iii) HIV cognitively impaired ($n = 54$). Age-matched and sex-matched plasma from healthy control participants (HIV seronegative, $n = 25$) were obtained from the Johns Hopkins University performance site. Demographic and clinical characteristics of the participants for cross-sectional analyses are summarized in Table 1, ART naive vs ART stable in eTable 1 ([links.ww.com/WNL/C210](https://www.ww.com/WNL/C210)), and longitudinal analyses in eTable 2. In cross sectional analyses, nadir CD4 was lower in HIV cognitively impaired compared with HIV cognitively normal ($p < 0.024$). Average age, current

Table 1 Baseline Clinical and Demographic Characteristics

Baseline characteristics	HIV _{SN} (n = 25)	HIV _{CN} (n = 41)	HIV _{CI} (n = 54)
Age (y)	42.26 (12.55)	44.12 (9.54)	45.17 (7.78)
Education (y)	nd	13.05 (1.96)	13.11 (2.73)
Sex (male)	56	92.7	77.8
Ethnicity (Caucasian)	60	78	79.6
AIDS	nd	63.4	74.1
Current CD4 (cells/mm ³)	nd	389.73 (226.38)	450.09 (280.67)
Nadir CD4 (cells/mm ³)	nd	192.85 (194.08)	162.24 (160.85)
Current ART	nd	68.3	74.07
Plasma viral load (≤ 50 copies/mL)	nd	69.2	72.2
CSF viral load (≤ 50 copies/mL)	nd	40.5	40.7


Abbreviations: ART = antiretroviral therapy; HIV_{CI} = HIV cognitively impaired; HIV_{CN} = HIV cognitively normal; HIV_{SN} = HIV seronegative; nd = no data. Data are expressed as % mean (\pm SD) as appropriate.

CD4, plasma viral load, and AIDS status were not statistically different between the groups (Table 1). There were overall group differences in current CD4 levels ($p < 0.028$), with HIV stably impaired cognition > HIV stably normal cognition > HIV worsening cognition > HIV impaired cognition and plasma viral load ($p < 0.032$) with HIV impaired cognition > HIV worsening cognition > HIV stably impaired cognition > HIV stably normal cognition, when participants were arranged according to longitudinal change in cognition (eTable 2).

Baseline Associations Between Plasma Eicosanoids, HIV Status, and ART

We detected and quantified 42 individual eicosanoids in plasma that were categorized based on the precursor molecule from which they were derived. These included metabolites of (i) eicosapentaenoic acid (EPA), (ii) docosahexaenoic acid (DHA), (ii) arachidonic acid (AA), and (iv) linoleic acid (LA). Most eicosanoids detected (38 of 42) were elevated in PWH compared with HIV seronegatives (Figure 1A). These included the EPA metabolites 5-HEPE, 8-HEPE, 9-HEPE, 11-HEPE, 12-HEPE, 15-HEPE, 18-HEPE, and 8, (9)-EpETE (Figure 1B); DHA metabolites 4-HDoHE, 8-HDoHE, 10-HDoHE, 11-HDoHE, 13-HDoHE, 14-HDoHE, 16-HDoHE, 17-HDoHE, and 19(20)-EpDPF (Figure 1B); AA metabolites 5-HETE, 8-HETE, 9-HETE, 11-HETE, 12-HETE, 15-HETE, 15-OxoETE, 8,9-DilHETrE, 5,12-DilHETE, 5,15-DilHETE, HXB3, LXA4, 8, (9)-EET, 11, (12)-EET, 14, (15)-EET, TXB2 (Figure 1C); and the LA metabolites 9-HODE, 13-HODE, 9,10-EpOME, and 15-HETrE (Figure 1D). The data shown prediction power of 100% at 5% FDR ($\alpha = 0.0531$). Several of these EPA metabolites including 8-HEPE, 9-HEPE, and 11-HEPE were below detectable limits in most HIV

Figure 1 Baseline Analysis of Plasma Eicosanoids in PWH and Healthy Seronegative Control Participants



Box plots show (A) EPA metabolites, (B) DHA metabolites, (C) AA metabolites, and (D) LA metabolites. Data show median and range with individual data points. HIV seronegative (n = 25) and PWH (n = 95). * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$. The nonparametric Wilcoxon signed-rank test with Benjamini-Hochberg FDR correction performed for 2-group comparisons. AA = arachidonic acid; DHA = docosahexaenoic acid; EPA = eicosapentaenoic acid; LA = linoleic acid; PWH = people with HIV.

seronegatives and were well above detectable limits in plasma from PWH. These data demonstrate that HIV infection is associated with a robust increase in plasma eicosanoids. When we separated groups based on ART use, there were no group differences in plasma eicosanoids between ART naive and PWH stably treated with ART (Figure 2, A–D). These data suggest that HIV infection is associated with a robust increase in plasma eicosanoids that is not fully resolved by ART.

Baseline Associations Between Plasma Eicosanoids and Cognition

We next compared the baseline plasma levels of eicosanoids with cognitive impairment status in PWH. We found that plasma levels of most eicosanoids were elevated in both HIV cognitively normal and HIV cognitively impaired compared with HIV seronegative (Figure 3, A–D). Eight EPA metabolites 5-HEPE, 8-HEPE, 9-HEPE, 11-HEPE, 12-HEPE, 15-HEPE, 18-HEPE, and 8, (9)-EpETE were elevated in HIV cognitively normal and HIV cognitively impaired compared with HIV seronegative (Figure 3A). DHA was decreased, and 10 DHA metabolites including 4-HDoHE, 8-HDoHE, 10-HDoHE, 11-HDoHE, 13-HDoHE, 14-HDoHE, 16-HDoHE, 17-HDoHE, and 19, (20)-EpDPF were elevated in HIV cognitively normal and HIV cognitively impaired compared with HIV seronegative (Figure 3B). We did not observe group differences in AA, but all 16 AA metabolites 5-HETE, 8-HETE, 9-HETE, 11-HETE, 12-HETE, 15-HETE, 15-OxoETE, 8, 9-DiHETE, 5, 12-DiHETE, 5, 15-DiHETE, HXB3, LXA4, 8, (9)-EET, 11, (12)-EET, 14, (15)-EET, and TXB2 were elevated in HIV cognitively normal and HIV cognitively impaired compared with HIV seronegative (Figure 3C). Four of 6 LA metabolites including 9-HODE, 13-HODE, 9, 10-EpOME, and 15-HETrE were also elevated in HIV cognitively normal and HIV cognitively impaired compared with HIV seronegative (Figure 3D). The data showed prediction power of 35% at 5% FDR ($\alpha = 0.05$) and 100% prediction power at 10% FDR ($\alpha = 0.10$). These data demonstrate that most plasma eicosanoids are elevated in PWH regardless of cognitive status.

Baseline Associations of Plasma Eicosanoids With Virologic and Immunologic Markers

In exploratory analyses, we found negative associations between baseline plasma levels of eicosanoids and current CD4 (8 EPA, 7 DHA, 15 AA, 4 LA), nadir CD4 (9 DHA, 6 EPA, 15 AA, 4 LA), 1 AA (TXB2) metabolite was associated with creatinine, 1 LA (12, 13 diHOME) metabolite was associated with bilirubin, 1 EPA and 1 AA metabolite were associated with aspartate aminotransferase, and 1 DHA, and 2 AA metabolites were associated with alanine transaminase. One DHA (4-HDoHE) metabolite was associated with cholesterol, high density lipoprotein (1 DHA, 7 AA, 1 LA); a single DHA metabolite was associated with white blood cell; 1 EPA and 1 DHA metabolites were associated with RBC; hemoglobin (2 EPA, 3 DHA, 1LA), hematocrit (1 EPA, 3DHA, 1LA), and 3 DHA metabolites were associated with MCHC; 2 DHA metabolites were associated with platelets, total lymphocyte count (4 DHA, 9 EPA, 13 AA, 4 LA); and a single LA metabolite was associated with basophil (Figure 4). There were also positive associations between


eicosanoids and age (1EPA, 2DHA, 1AA), education (3 DHA, 3 EPA), glucose (1 AA), calcium (1 EPA, 4 DHA, 2 AA, 4 LA), 1 AA and 1 LA metabolite associated with total protein, a single AA metabolite was associated with triglyceride levels, a single AA metabolite was associated with platelet count, neutrophil counts (1EPA, and 3AA), and eosinophil count associated with (3 DHA, 1 AA, and 1 LA) (Figure 4). The most robust associations show that low current CD4, nadir CD4, high density lipoprotein, and total lymphocyte counts are associated with higher levels of proinflammatory eicosanoids. They also show that higher calcium levels and neutrophil counts are associated with higher levels of plasma eicosanoids (Figure 4). Many of these associations did not remain after FDR correction with the exceptions of current and nadir CD4 association with multiple eicosanoids (eFigure 1, [links.lww.com/WNL/C210](https://www.lww.com/WNL/C210)). The data shown prediction power of 100% at 5% FDR ($\alpha = 0.02$).

We further compared the plasma eicosanoids level in HIV seronegative participants, virally suppressed (<50 copies/mL) PWH, and not fully suppressed (≥ 50 copies/mL) individuals (Figure 5). Elevated plasma eicosanoids were similar in virally suppressed and not fully suppressed individuals, and none of the eicosanoids measured were different between these 2 groups. These data suggest that most plasma eicosanoids are elevated in PWH regardless of viral suppression.

Plasma Eicosanoids Are Negatively Associated With Performance on Working Memory Tasks in Exploratory Analyses


We next determined in exploratory analyses whether baseline plasma levels of eicosanoids were cross-sectionally associated with cognition in PWH. There were no associations between baseline plasma eicosanoid levels and global deficit score, speed of information processing (SIP), learning, recall, or motor function. Several eicosanoids were negatively associated with verbal fluency, executive function, and working memory. Seven eicosanoid metabolites (3 DHA, 3 AA, 1 LA) were associated with verbal fluency, 4 eicosanoid metabolites (2 EPA, 2 DHA) were associated with executive function, and striking 30 eicosanoid metabolites (5 EPA, 7 DHA, 13 AA, 5 LA) were associated with working memory performance (Figure 6A). When we only included HIV cognitively normal in the analysis, we observed only a small number of associations between plasma eicosanoids and cognitive domain performance. A single AA metabolite was negatively associated with global deficit score, and 1 EPA and 1 AA metabolite were negatively associated with executive function (Figure 6B). There were also positive associations between eicosanoids and global deficit score (1 DHA, and 1 LA), SIP (1 LA), and motor function (1 EPA, 1 AA, 1 LA) (Figure 6B). However, when we only included HIV cognitively impaired in the analysis, a negative association of 4 eicosanoids (3 DHA, 1AA) with verbal fluency and 13 eicosanoids (3 EPA, 9 AA, and 1LA) with working memory performance remained (Figure 6C). There were also positive associations between eicosanoids and learning (2 DHA) and recall (3 DHA, 3 AA, 1 LA) (Figure 6). These findings suggest that elevated plasma levels of eicosanoids in PWH may be associated with worse

Figure 2 Baseline Analysis of Plasma Eicosanoids in Healthy Seronegative Control Participants and People with HIV Who Are ART Naive Or on a Stable ART Regimen




Box plots show (A) EPA metabolites, (B) DHA metabolites, (C) AA metabolites, and (D) LA metabolites. Data show median and range with individual data points. HIV seronegative (n = 25), ART stable (n = 66), and ART naive (n = 29). * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$ increased compared with HIV seronegative. ### $p < 0.001$ decreased compared with HIV seronegative. The Kruskal-Wallis test with the Dunn post hoc comparison test performed for 3-group comparisons. AA = arachidonic acid; ART = antiretroviral therapy; DHA = docosahexaenoic acid; EPA = eicosapentaenoic acid; LA = linoleic acid.

Figure 3 Baseline Analysis of Plasma Eicosanoids in Healthy Seronegative Control Participants, Cognitively Normal, and Cognitively Impaired



People with HIVBox plots show (A) EPA metabolites, (B) DHA metabolites, (C) AA metabolites, and (D) LA metabolites. Data show median and range with individual data points. HIV seronegative (n = 25), HIV_{CN} = cognitively normal (n = 41), and HIV_{CI} = cognitively impaired (n = 54). **p* < 0.05, ***p* < 0.01, ****p* < 0.001 increased compared with HIV seronegative. #*p* < 0.05, ##*p* < 0.01 decreased compared with HIV seronegative. The Kruskal-Wallis test with the Dunn post hoc comparison test performed for 3-group comparisons. AA = arachidonic acid; DHA = docosahexaenoic acid; EPA = eicosapentaenoic acid; LA = linoleic acid.

Figure 4 Correlation Plot Showing the Relationships of Plasma Eicosanoid Levels to Demographic, Virologic, and Clinical Markers



The value of effect size of Spearman correlation and the direction of the relationship is depicted by color from 1.0 in dark blue to -1.0 in dark red. The value of the effect size is considered low if the value of r is around 0.1, medium if around 0.3, and large if r is greater than 0.5. Most effect sizes in this analysis were in the medium to high value range. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$. Spearman rank correlation.

performance on neuropsychological tests assessing working memory, and to a lesser extent verbal fluency, and executive function. None of these associations remained after FDR correction (eFigure 2, links.lww.com/WNL/C210). The data shown prediction power of 100% at 5% FDR ($\alpha = 0.0419$).

Longitudinal Associations Between Plasma Eicosanoids, Cognition, and Plasma Markers


In initial longitudinal analyses, we sought to determine whether plasma eicosanoid levels at baseline were prognostic indicators of cognitive function at the next study visit. All but 1 plasma eicosanoids were similar between all groups (eFigure 3, A-D, links.lww.com/WNL/C210). The DHA metabolite 17-HDoHE was elevated at baseline in plasma of HIV improving cognition compared with HIV stably normal cognition (eFigure 3B). These data are consistent with the protective and anti-

inflammatory properties of these omega 3 DHA metabolites and suggest that plasma levels of most eicosanoids are not prognostic indicators for change in cognition.

We next determined whether plasma levels of eicosanoids accompanied changes in cognition using plasma samples from visit 2. None of the eicosanoids measured at visit 2 were different across the 4 HIV change groups (eFigure 4, A-D, links.lww.com/WNL/C210). The data shown prediction power of 2% at 5% FDR ($\alpha = 0.05$) and a maximum prediction power of 37% at $\alpha = 0.297$. These findings suggest that plasma eicosanoid levels are not associated with changes in cognition after the change in cognitive function has occurred.


When we looked at associations between change in virologic/blood markers and change in plasma eicosanoid concentrations,

Figure 5 Baseline Plasma Eicosanoids in Healthy Seronegative Control Participants and People with HIV With Virally Suppressed (<50 Copies/mL) and Not Fully Suppressed (>50 Copies/mL) Individuals



Box plots show (A) EPA metabolites, (B) DHA metabolites, (C) AA metabolites, and (D) LA. Data show median and range with individual data points. HIV seronegative (n = 25), viral load <50 copies (n = 43), and viral load >50 copies (n = 52). **p* < 0.05, ***p* < 0.01, ****p* < 0.001 increased compared with HIV seronegative. The Kruskal-Wallis test with the Dunn post hoc comparison test performed for 3-group comparisons. AA = arachidonic acid; DHA = docosahexaenoic acid; EPA = eicosapentaenoic acid; LA = linoleic acid.

Figure 6 Correlation Plots Showing the Relationships of Plasma Eicosanoid Levels to Global Cognitive Function and Performance in Individual Cognitive Domains



(A) Relationship of baseline plasma eicosanoid levels in all HIV-infected patients to overall cognitive function (global) and performance in verbal, executive function, SIP, learning, recall, working memory, and motor function. (B) Relationship of baseline plasma eicosanoid levels in cognitively normal HIV-infected patients (HIV_{CN}) to overall cognitive function (global) and performance in the indicated cognitive domains. (C) Relationship of baseline plasma eicosanoid levels in cognitively impaired HIV-infected patients (HIV_{CI}) to overall cognitive function (global) and performance in the indicated cognitive domains. The value of effect size of Spearman correlation and the direction of the relationship is depicted by color from 1.0 in dark blue to -1.0 in dark red. The value of the effect size is considered low if the value of r is around 0.1, medium if around 0.3, and large if r is greater than 0.5. Most effect sizes in this analysis were in the medium value range. * $p < 0.05$ and ** $p < 0.01$. Spearman rank correlation. AA = arachidonic acid; DHA = docosahexaenoic acid; EPA = eicosapentaenoic acid; LA = linoleic acid; SIP = speed of information processing.

we found associations between change in viral load and change in 6 of the 42 eicosanoids that included the 1 EPA metabolite 15-HpEPE; 3 DHA metabolites 13-, 17-HDoHE, and DHA; 1 AA metabolite AA; and 1 LA metabolites 9, 10-diHOME (eFigure 5, links.lww.com/WNL/C210). There were similarly strong associations between change in plasma creatinine and change in 35 of the 42 eicosanoids that included the 9 EPA metabolites 5-HEPE, 8-, 9-, 11-, 12-, 15-, 8, (9)-EpETE, 15-OxoETE, and 15-HpEPE; 9 DHA metabolites 4-, 10-, 11-, 13-, 14-, 16-, 17-HDoHE, 19, 20-EpDPE, and DHA; 14 AA metabolites 5-, 8-, 9-, 11-, 12-, 15-HETE, 8, (9)-, 11(12)-, 14, (15)-EET, 5, (15)-, 5, (12) DiHETE, HXB3, 8, (9)-DiHETrE, and AA; and 3 LA metabolites 13-HODE, 9, 10-EpOME, and 15-HETrE (eFigure 5). A single association was found between change in the LA metabolite 9,

10-diHOME and bilirubin, and 3 LA metabolites (9-, 13-HODE, and 12, 13-diHOME) were associated with change in triglyceride levels (eFigure 5). There were 2 associations found between change in low density lipoprotein levels and 2 LA metabolites that included 9, 10- and 12, 13-diHOME. Two associations between white blood cell count and 2 eicosanoids that included DHA and AA. There were 6 associations between hemoglobin and 1 EPA metabolite (5-HEPE), 4 DHA (11-, 13-, 17-HDoHE, and DHA), and 1 AA metabolite included AA. Two associations between neutrophil and 1 EPA (12-HEPE) and 1 DHA (8-HDoHE) metabolite were also observed (eFigure 5). Looking at change in eicosanoid levels and change in virologic/blood markers, we found that 6 of 42 eicosanoids were correlated with plasma viral load and 35 of 42 eicosanoids were

correlated with creatinine (eFigure 5). The most robust associations suggest that increases in plasma viral load were strongly associated with increases in plasma eicosanoids, reductions in kidney function (as suggested by creatinine reductions). None of these associations remained after FDR correction (eFigure 6). The data shown prediction power of 24% at 5% FDR ($\alpha = 0.05$) and a maximum prediction power of 42.4 at 10% FDR ($\alpha = 0.10$).

Discussion

HIV infection results in a robust inflammatory response with increased plasma levels of cytokines, chemokines, and eicosanoids (see reference 4 for a review). A prominent role for these inflammatory mediators is to regulate the immune response to HIV infection. ART suppresses HIV replication, largely stabilizes immune function and decreases levels of most (but not all) cytokines and chemokines. However, the possible effects of ART on eicosanoid metabolism have not been studied. Here, we provide evidence that ART may not substantially reduce elevated levels of eicosanoids in PWH, suggesting that a sustained immune dysregulation with ART may involve chronically elevated levels of proinflammatory eicosanoids. Plasma eicosanoid levels were negatively associated with current CD4, nadir CD4, and lymphocyte counts. Eicosanoids with proinflammatory effects (LA and AA metabolites) were positively associated with plasma viral load. Longitudinal analyses showed that eicosanoid levels rise in accordance with viral load and with plasma creatinine, implicating elevations of eicosanoids with impairments in kidney function. Despite the associations of eicosanoid levels with viral loads, elevated plasma eicosanoids were similar in virally suppressed (<50 copies/mL) and not fully suppressed (>50 copies/mL) individuals. These data suggest that HIV infection is associated with a robust production of eicosanoids that is not substantially reduced by ART and is associated with impairments in cognition, immune dysregulation, and damage to peripheral organs.

Eicosanoids are a family of bioactive lipids produced primarily through the metabolism of AA, LA, EPA, and DHA. These bioactive lipids serve a wide variety of signaling functions including regulation of the inflammatory response, immune function, and vasodilation/constriction, among others (see reference 5 for a recent review). Eicosanoid metabolism is complex, often involving multiple metabolic steps within a single cell. Each of the metabolites produced in a metabolic pathway have independent functions, with some metabolites produced later in series opposing the functions of earlier metabolites, thus serving to limit the duration of some physiologic responses such as an inflammatory reaction. However, prolonged activation of these metabolic pathways under conditions such as those produced by HIV infection can result in a deregulated inflammatory and immune response. Although we cannot precisely determine a mechanism for this sustained eicosanoid response in ART-treated PWH from our results, there is a considerable amount of evidence

that the gut microbiome may play an important role. CD4⁺ cells lining the gut are largely lost with HIV infection and do not fully re-establish with ART. This loss of CD4⁺ cells in PWH increases gut permeability and results in bacterial-derived lipopolysaccharide leaking into circulation.¹⁶ Lipopolysaccharides in addition to viral infection are potent activators of toll-like receptors (TLRs) that are linked with eicosanoid metabolism.

TLRs belong to a family of pattern recognition receptors that play key roles in initiating an innate immune response that involves a rapid activation of arachidonic acid metabolism in leukocytes, platelets, and dendritic cells^{17,18} (among others). The HIV coat protein gp120 interacts with TLR2 and TLR4 in the presence of heparan sulfate¹⁹ and inhibits the activation of TLR9 in plasma dendritic cells (this latter effect presumably limits the ability of the host to produce some antiviral and inflammatory mediators).²⁰ HIV ssRNA binds and activates TLR7 and TLR8 in mononuclear cells during viral internalization.^{21,22} After HIV infection, the expression of both TLR2 and TLR4 is increased in monocyte-derived macrophages, PBMCs, and dendritic cells.^{23,24} A number of other viral components interact with TLRs including p17 and gp41 that activate TLR1 and TLR2, p24 activates TLR2 and TLR6,²⁵ and Tat directly binds TLR4 mRNA to more than double its half-life with a resultant decrease in TLR4 expression.²⁶ Although it is not entirely clear which viral components contribute to the maintenance of the eicosanoid response in virally suppressed PWH, there is a great deal of evidence suggesting that nonstructural proteins such as Tat continue to be produced despite viral suppression.²⁷

In addition to initiating an innate immune response, eicosanoids play important roles in regulating the interactions between innate and adaptive immune responses including activation, proliferation, migration, differentiation, antibody and cytokine production in lymphocytes, and other leukocytes.²⁸ In this study, we found a negative association between current CD4 count and plasma eicosanoids levels and a positive association between viral load and eicosanoid levels. The association between high viral loads and low CD4 counts is a common finding in PWH because the virus replicates in and kills CD4⁺ T cells. Presumably, a higher viral load would also increase the production of eicosanoids through activation of TLRs as described above, but it is also possible that eicosanoids directly regulate the activity of CD4⁺ cells. Both CD4⁺ and CD8⁺ cells express enzymes for arachidonic acid metabolism including COX1, COX2, 5-LOX, and PGG2.²⁹ PGE2 can differentially regulate apoptosis and inhibit proliferation depending on the subpopulation and activation status of CD4 and CD8 cells.³⁰ LTB4 signaling through BLT1 promotes activation, cytokine production, chemotaxis, endothelial adhesion, and migration of macrophages and CD4⁺ cells into tissues including brain.³¹ Indeed, the elevated numbers of macrophages and T cells in brain parenchyma of PWH is a common finding.³² We also observed that ART did not substantially reduce circulating levels of eicosanoids in addition to a negative association with

low nadir CD4. Together, these data suggest that the initial damage to the immune system may have long-term consequences that delimit the eicosanoid response to viral infection. Indeed, low nadir CD4 has been consistently associated with faster disease progression and worse cognitive outcomes in multiple cohorts of PWH.^{33,34}

Although the mechanisms responsible for a deregulated eicosanoid response are likely multifactorial, in exploratory analyses, we found evidence for reduced antioxidant capacity as evidenced by a negative association between plasma bilirubin and eicosanoid levels. Bilirubin is a powerful antioxidant that suppresses inflammation by inhibiting the activities of secretory phospholipase A₂ (sPLA₂).^{35,36} Secretory PLA₂ is responsible for the production of AA from membrane phospholipids that are subsequently metabolized into numerous proinflammatory eicosanoids through COX, LOX, or cytochrome P450 pathways. It is also possible that reduced bilirubin levels contribute to increased eicosanoids indirectly through a disinhibition of inducible nitric oxide synthase (iNOS). Bilirubin has been shown to inhibit hepatic iNOS expression and nitric oxide (NO) production in response to endotoxin in rats,³⁷ and previous studies have shown that NO increases the production of eicosanoids.³⁸⁻⁴⁰ NO together with cGMP promote COX-2 expression and the production of PGE₂ in human granulosa cells through cAMP response element-binding protein signaling,⁴⁰ and PGE₂ has been shown to further promote NO production through IFN γ in cultured rat microglia.⁴¹ In PWH, a negative association of bilirubin and cardiovascular disease, insulin resistance, and DNA damage has been previously reported.^{42,43} These data combined with the current findings suggest that reduced levels of circulating bilirubin may contribute to the overproduction of eicosanoids.

There is a strong association between peripheral immune activation, inflammation, eicosanoid metabolism, and neurologic dysfunction that is apparent in multiple neurodegenerative conditions that include a rich literature on roles for eicosanoids in regulating cognitive performance.⁴⁴⁻⁴⁶ Peripheral immune activation and inflammation are known to activate brain resident glia with consequent increases in the expression of PLA₂, the rate-limiting enzyme in AA production. In this study, we found a negative correlation between most of the plasma eicosanoids we measured and working memory, with a smaller number of eicosanoids showing a negative correlation with executive function. In exploratory analyses, the observation that worse performance on tasks assessing working memory and executive functions was associated with higher levels of almost all eicosanoids suggests a deregulated inflammatory response, despite the production of eicosanoids whose function is to limit the duration and extent of the response. In addition to prominent roles for eicosanoids in inflammation, they also play important roles in basal tone and platelet activation. For example, HETEs exhibit prohypertensive effects through vasoconstriction and antihypertensive effects through natriuresis.^{47,48} Platelet activation and apoptotic pathways are increased in PWH, despite virologic suppression,⁴⁹ and

thrombocytopenia is a common finding in PWH. In addition to roles in vascular and tissue repair, they play central roles in innate immune activation by directly interacting with leukocytes and secreting cytokines and chemokines. These data suggest that elevated eicosanoids in PWH may not only directly contribute to cognitive impairments but also restrict neurovascular flow and promote platelet activation.

Although we believe the findings from this study provide a potential mechanistic explanation for sustained inflammation in virally suppressed PWH, there are some shortcomings. This study was conducted with a relatively small number of samples from PWH that were obtained from a single cohort. The PWH of this study were almost exclusively male. Based on known sex differences in the prevalence and etiology of autoimmune diseases, inflammatory diseases, and neurodegenerative conditions, the associations of eicosanoids with clinical outcomes and cognition that we report here may not be directly applicable to HIV-infected women. Future studies should re-evaluate potential roles of eicosanoids as drivers of sustained inflammation in a larger sample size obtained from multiple cohorts with diverse demographics and risk factors.

Our findings suggest that HIV infection is associated with a robust increase in plasma eicosanoids that is not resolved by ART. Although there was an association between low nadir CD4, low current CD4, high viral load, and elevated eicosanoids, those individuals with viral suppression below detectable limits did not completely resolve plasma eicosanoid levels. Elevated eicosanoids were associated with poorer cognitive performance. Our data suggest impairment in the self-limiting aspects of an inflammatory eicosanoid response.

Study Funding

This study was funded by AA0017408, MH077542, MH075673, AG034849 (NJH and JCM), MH071150 (NS), DA61427, MH61427, NS56883 (LC), MH22005, HHSN271201000027C, and HHSN271201000030C (CNS HIV Antiretroviral Therapy Effects Research [CHARTER]) Study (IG & SL).

Disclosure

The authors report no relevant disclosures. Go to Neurology.org/N for full disclosures.

Acknowledgment

We would like to thank Dr. Ratnam Bandaru for his technical contributions to this work that included mass spectrometric analysis and to Cynthia Lo for her assistance in preparing demographic tables. We would also like to thank Drs. Richard Skolasky, Florin Vaida, and Ian Abramson for additional statistical support.

Publication History

Received by *Neurology* January 28, 2022. Accepted in final form May 20, 2022. Submitted and externally peer reviewed. The handling editor was Linda Hershey, MD, PhD, FAAN.

Appendix Authors

Name	Location	Contribution
Pragney Deme, PhD	Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD	Drafting/revision of the manuscript for content, including medical writing for content; Study concept or design; Analysis or interpretation of data; Additional contributions: prepared figures, performed statistical analyses, reviewed and edited the manuscript. Interpreted experimental findings and wrote the initial draft of the manuscript.
Mohammed Moniruzzaman, PhD	Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD	Provided samples from the CHARTER cohort, contributed to the analysis of cognitive testing data, interpretation of data and editing of the manuscript.
David Moore, PhD	HIV Neurobehavioral Research Program and Departments of Neurosciences and Psychiatry, School of Medicine, University of California, San Diego, La Jolla, CA	Provided samples from the CHARTER cohort and directs the HNRC at UCSD. Edited the manuscript
Robert Heaton, PhD	HIV Neurobehavioral Research Program and Departments of Neurosciences and Psychiatry, School of Medicine, University of California, San Diego, La Jolla, CA	Provided samples from the CHARTER cohort, oversaw sample collection and contributed to interpretation of data and editing of the manuscript.
Ronald Ellis, MD, PhD	HIV Neurobehavioral Research Program and Departments of Neurosciences and Psychiatry, School of Medicine, University of California, San Diego, La Jolla, CA	Provided samples from the CHARTER cohort, contributed to interpretation of data and editing of the manuscript
Scott Letendre, MD	HIV Neurobehavioral Research Program and Departments of Neurosciences and Psychiatry, School of Medicine, University of California, San Diego, La Jolla, CA	Oversaw all aspects of experimental design, analyses, data interpretation, and manuscript preparation.
Norman Haughey, PhD	Department of Neurology, Johns Hopkins University School of Medicine; Department of Psychiatry, Johns Hopkins University School of Medicine, Baltimore, MD	Drafting/revision of the manuscript for content, including medical writing for content; Analysis or interpretation of data; Additional contributions: prepared figures, performed statistical analyses, reviewed and edited the manuscript.

References

1. Egger M, May M, Chêne G, et al; ART Cohort Collaboration. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. *Lancet (London, England)*. 2002;360(9327):119-129.
2. Eggers C, Arendt G, Hahn K, et al; German Association of Neuro-AIDS und Neuro-Infectiology DGNANI. HIV-1-associated neurocognitive disorder: epidemiology, pathogenesis, diagnosis, and treatment. *J Neurol*. 2017;264(8):1715-1727.
3. Chen L, Deng H, Cui H, et al. Inflammatory responses and inflammation-associated diseases in organs. *Oncotarget*. 2018;9(6):7204-7218.
4. Saylor D, Dickens AM, Sacktor N, et al. HIV-associated neurocognitive disorder—pathogenesis and prospects for treatment. *Nat Rev Neurol*. 2016;12(5):309-248.
5. Esser-von Bieren J. Immune-regulation and -functions of eicosanoid lipid mediators. *Biol Chem*. 2017;398(11):1177-1191.
6. Griffin DE, Wesselingh SL, McArthur JC. Elevated central nervous system prostaglandins in human immunodeficiency virus—associated dementia. *Ann Neurol*. 1994;35(5):592-597.
7. Frolidi M, Castagna A, Parma M, et al. Mediator release in cerebrospinal fluid of human immunodeficiency virus-positive patients with central nervous system involvement. *J Neuroimmunol*. 1992;38(1-2):155-161.
8. Wang D, Melancon JK, Verbese J, et al. Microvascular endothelial dysfunction and enhanced thromboxane and endothelial contractility in patients with HIV. *J AIDS Clin Res*. 2013;4(12):267.
9. Bertin J, Barat C, Methot S, Tremblay MJ. Interactions between prostaglandins, leukotrienes and HIV-1: possible implications for the central nervous system. *Retrovirology*. 2012;9(1):4.
10. Marcotte TD, Deutsch R, Michael BD, et al; CHARTER Group. A concise panel of biomarkers identifies neurocognitive functioning changes in HIV-infected individuals. *J Neuroimmune Pharmacol*. 2013;8(5):1123-1135.
11. Dickens AM, Anthony DC, Deutsch R, et al. Cerebrospinal fluid metabolomics implicate bioenergetic adaptation as a neural mechanism regulating shifts in cognitive states of HIV-infected patients. *AIDS*. 2015;29(5):559-569.
12. Heaton RK, Clifford DB, Franklin DR Jr., et al; CHARTER Group. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. *Neurology*. 2010;75(23):2087-2096.
13. Carey CL, Woods SP, Gonzalez R, et al; HNRC Group. Predictive validity of global deficit scores in detecting neuropsychological impairment in HIV infection. *J Clin Exp Neuropsychol*. 2004;26(3):307-319.
14. Cysique LA, Franklin D Jr, Abramson I, et al; CHARTER Group; HNRC Group. Normative data and validation of a regression based summary score for assessing meaningful neuropsychological change. *J Clin Exp Neuropsychol*. 2011;33(5):505-522.
15. Khuder SS, Chen S, Letendre S, et al. Impaired insulin sensitivity is associated with worsening cognition in HIV-infected patients. *Neurology*. 2019;92(12):e1344-e1353.
16. Ancuta P, Kamat A, Kunstman KJ, et al. Microbial translocation is associated with increased monocyte activation and dementia in AIDS patients. *PLoS One*. 2008;3(6):e2516.
17. Ebert R, Cumbana R, Lehmann C, et al. Long-term stimulation of toll-like receptor-2 and -4 upregulates 5-LO and 15-LO-2 expression thereby inducing a lipid mediator shift in human monocyte-derived macrophages. *Biochim Biophys Acta Mol Cell Biol Lipids*. 2020;1865(9):158702.
18. Salvi V, Vaira X, Gianello V, et al. TLR signalling pathways diverge in their ability to induce PGE2. *Mediat Inflamm*. 2016;2016:5678046.
19. Nazi A, Kafka JK, Ferreira VH, et al. HIV-1 gp120 induces TLR2- and TLR4-mediated innate immune activation in human female genital epithelium. *J Immunol*. 2013;191(8):4246-4258.
20. Martinelli E, Cicala C, Van Ryk D, et al. HIV-1 gp120 inhibits TLR9-mediated activation and IFN- α secretion in plasmacytoid dendritic cells. *Proc Natl Acad Sci USA*. 2007;104(9):3396-3401.
21. Rawat P, Teodorof-Diedrich C, Spector SA. Human immunodeficiency virus type-1 single-stranded RNA activates the NLRP3 inflammasome and impairs autophagic clearance of damaged mitochondria in human microglia. *Glia*. 2019;67(5):802-824.
22. Han X, Li X, Yue SC, et al. Epigenetic regulation of tumor necrosis factor α (TNF α) release in human macrophages by HIV-1 single-stranded RNA (ssRNA) is dependent on TLR8 signaling. *J Biol Chem*. 2012;287(17):13778-13786.
23. Hernandez JC, Artega J, Paul S, Kumar A, Latz E, Urququi-Inchima S. Up-regulation of TLR2 and TLR4 in dendritic cells in response to HIV type 1 and coinfection with opportunistic pathogens. *AIDS Res Hum Retroviruses*. 2011;27(10):1099-1109.
24. Brown JN, Kohler JJ, Coberley CR, Sleasman JW, Goodenow MM. HIV-1 activates macrophages independent of Toll-like receptors. *PLoS One*. 2008;3(12):e3664.
25. Henrick BM, Yao XD, Rosenthal KL; INFANT Study Team. HIV-1 structural proteins serve as PAMPs for TLR2 heterodimers significantly increasing infection and innate immune activation. *Front Immunol*. 2015;6:426.
26. O'Hara SP, Small AJ, Gajdos GB, Badley AD, Chen XM, Larusso NF. HIV-1 tat protein suppresses cholangiocyte toll-like receptor 4 expression and defense against *Cryptosporidium parvum*. *J Infect Dis*. 2009;199(8):1195-1204.
27. Henderson LJ, Johnson TP, Smith BR, et al. Presence of tat and transactivation response element in spinal fluid despite antiretroviral therapy. *AIDS*. 2019;33(suppl 2):S145-S157.
28. Wei J, Gronert K. Eicosanoid and specialized proresolving mediator regulation of lymphoid cells. *Trends Biochem Sci*. 2019;44(3):214-225.
29. Rocca B, Spain LM, Ciabattini G, Patrono C, FitzGerald GA. Differential expression and regulation of cyclooxygenase isozymes in thymic stromal cells. *J Immunol*. 1999;162(8):4589-4597.
30. Sreeramkumar V, Fresno M, Cuesta N. Prostaglandin E2 and T cells: friends or foes? *Immunol Cell Biol*. 2012;90(6):579-586.
31. Pires-Lapa MA, Koga MM, da Silva IA Jr, Filgueiras LR, Janca S. Leukotriene B4 modulation of murine dendritic cells affects adaptive immunity. *Prostaglandins Other Lipid Mediat*. 2019;141:34-39.

32. Anderson AM, Fennema-Notestine C, Umlauf A, et al; CHARTER Group. CSF biomarkers of monocyte activation and chemotaxis correlate with magnetic resonance spectroscopy metabolites during chronic HIV disease. *J Neurovirol.* 2015;21(5):559-567.
33. Valcour V, Yee P, Williams AE, et al. Lowest ever CD4 lymphocyte count (CD4 nadir) as a predictor of current cognitive and neurological status in human immunodeficiency virus type 1 infection—The Hawaii aging with HIV cohort. *J Neurovirol.* 2006;12(5):387-391.
34. Wojna V, Skolasky RL, Hechavarria R, et al. Prevalence of human immunodeficiency virus-associated cognitive impairment in a group of Hispanic women at risk for neurological impairment. *J Neurovirol.* 2006;12(5):356-364.
35. Jameel NM, Frey BM, Frey FJ, Gowda TV, Vishwanath BS. Inhibition of secretory phospholipase A 2 enzyme by bilirubin: a new role as endogenous anti-inflammatory molecule. *Mol Cell Biochem.* 2005;276(1-2):219-225.
36. Joshi V, Umashankara M, Ramakrishnan C, et al. Dimethyl ester of bilirubin exhibits anti-inflammatory activity through inhibition of secretory phospholipase A2, lipoxygenase and cyclooxygenase. *Arch Biochem Biophys.* 2016;598:28-39.
37. Wang WW, Smith DLH, Zucker SD. Bilirubin inhibits iNOS expression and NO production in response to endotoxin in rats. *Hepatology.* 2004;40(2):424-433.
38. Davidge ST, Baker PN, Laughlin MK, Roberts JM. Nitric oxide produced by endothelial cells increases production of eicosanoids through activation of prostaglandin H synthase. *Circ Res.* 1995;77(2):274-283.
39. Sadekuzzaman M, Kim Y. Nitric oxide mediates antimicrobial peptide gene expression by activating eicosanoid signaling. *PLoS One.* 2018;13(2):e0193282.
40. Fang L, Chang H-M, Cheng J-C, Leung PCK, Sun Y-P. Nitric oxide and cGMP induce COX-2 expression and PGE2 production in human granulosa cells through CREB signaling pathway. *J Clin Endocrinol Metab.* 2015;100(2):E262-E269.
41. Nagano T, Nishiyama R, Sanada A, et al. Prostaglandin E2 potentiates interferon- γ -induced nitric oxide production in cultured rat microglia. *J Neurochem.* 2017;140(4):605-612.
42. Marconi VC, Duncan MS, So-Armah K, et al. Bilirubin is inversely associated with cardiovascular disease among HIV-positive and HIV-negative individuals in VACS (veterans aging cohort study). *J Am Heart Assoc.* 2018;7(10):e007792.
43. Kolgiri V, Nagar V, Patil V. Association of serum total bilirubin and plasma 8-OHdG in HIV/AIDS patients. *Interv Med Appl Sci.* 2018;10(2):76-82.
44. Panickar KS, Bhatena SJ. Control of fatty acid intake and the role of essential fatty acids in cognitive function and neurological disorders. In: Montmayeur JP, le Coutre J, eds. *Fat Detection: Taste, Texture, and Post Ingestive Effects.* Boca Raton (FL): CRC Press/Taylor & Francis; 2010.
45. Liu X, Davis CM, Alkayed NJ. P450 eicosanoids and reactive oxygen species interplay in brain injury and neuroprotection. *Antioxid Redox Signal.* 2018;28(10):987-1007.
46. Nelson JW, Young JM, Borkar RN, et al. Role of soluble epoxide hydrolase in age-related vascular cognitive decline. *Prostaglandins Other Lipid Mediat.* 2014;113-115:30-37.
47. Zhang B, Lai G, Liu X, Zhao Y. Alteration of epoxyeicosatrienoic acids in the liver and kidney of cytochrome P450 4f2 transgenic mice. *Mol Med Rep.* 2016;14(6):5739-5745.
48. Miyata N, Roman RJ. Role of 20-hydroxyeicosatetraenoic acid (20-HETE) in vascular system. *J Smooth Muscle Res.* 2005;41(4):175-193.
49. Mesquita EC, Hottz ED, Amancio RT, et al. Persistent platelet activation and apoptosis in virologically suppressed HIV-infected individuals. *Sci Rep.* 2018;8(1):14999.

Neurology[®]

Association of Plasma Eicosanoid Levels With Immune, Viral, and Cognitive Outcomes in People With HIV

Pragney Deme, Mohammed Moniruzzaman, David Moore, et al.
Neurology 2022;99:e1251-e1264 Published Online before print July 18, 2022
DOI 10.1212/WNL.0000000000200945

This information is current as of July 18, 2022

Updated Information & Services	including high resolution figures, can be found at: http://n.neurology.org/content/99/12/e1251.full
References	This article cites 48 articles, 8 of which you can access for free at: http://n.neurology.org/content/99/12/e1251.full#ref-list-1
Citations	This article has been cited by 1 HighWire-hosted articles: http://n.neurology.org/content/99/12/e1251.full##otherarticles
Subspecialty Collections	This article, along with others on similar topics, appears in the following collection(s): All Neuropsychology/Behavior http://n.neurology.org/cgi/collection/all_neuropsychology_behavior HIV http://n.neurology.org/cgi/collection/hiv HIV dementia http://n.neurology.org/cgi/collection/hiv_dementia
Permissions & Licensing	Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: http://www.neurology.org/about/about_the_journal#permissions
Reprints	Information about ordering reprints can be found online: http://n.neurology.org/subscribers/advertise

Neurology® is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.

